<table sstyle="width:80%" align="center" border=1>
<tr>
<th>mv</th>
<th>dw</th>
<th>HMMCrowd</th>
</tr>
<tr>
<td width=33%>
[21, 23] Zostavax.<br>[26, 27] Zostavax<br>[66, 70] (Zostavax refrigerated)<br>[76, 80] (Zostavax frozen)<br></td>
<td width=33%>
[16, 23] refrigerator-stable formulation of Zostavax.<br>[25, 27] vaccine Zostavax<br>[62, 70] refrigerator-stable formulation (Zostavax refrigerated)<br>[75, 80] formulation (Zostavax frozen)<br>[146, 155] glycoprotein enzyme-linked immunosorbent assay (gpELISA)<br>[353, 354] Zostavax<br></td>
<td width=33%>
[16, 23] refrigerator-stable formulation of Zostavax.<br>[25, 27] vaccine Zostavax<br>[62, 80] refrigerator-stable formulation (Zostavax refrigerated) with those of the current formulation (Zostavax frozen)<br>[134, 138] -zoster virus (<br>[139, 156] ) antibody responses were measured by a glycoprotein enzyme-linked immunosorbent assay (gpELISA).<br>[206, 207] refrigerated<br>[237, 242] (refrigerated formulation/frozen formulation)<br>[306, 311] refrigerated and the frozen formulation<br>[348, 354] refrigerator-stable formulation of Zostavax<br>[365, 368] frozen formulation;<br></td>
</tr>
